Page 1

Biolnvent Q1 INTERIM REPORT JANUARY 1 - MARCH 31 , 2021 Events in the quarter PROJECT UPDATES ⚫ ( R ) Biolnvent Phase 1 / 2a data suggest BI - 1206 restores activity of rituximab in re- lapsed non - Hodgkin's lymphoma patients . • Biolnvent enrolled first patient in a Phase 1 / 2a trial of the first - in - class anti - TNFR2 antibody BI - 1808 for the treatment of patients with solid tumors and CTCL . • Biolnvent and Transgene enrolled first patient in Phase 1 / 2a trial of novel oncolytic virus BT - 001 in solid tumors . ⚫ ( R ) Biolnvent streamlined agreement with CRUK on anti - FcyRIIB antibody , BI - 1206 , ahead of Phase 1/2 data . In exchange for a one - off payment of GBP 2.5 million , the revised deal simplifies and reduces BioInvent's obligations to CRUK . • Biolnvent presented proof - of - concept data on anti - FcyRIIB antibody BI - 1607 at AACR Annual Meeting 2021 . FINANCING ⚫ ( R ) Biolnvent successfully carried out a directed share issue of approximately SEK 962 million ( USD 116 million ) . Events after the period • BioInvent received IND approval for Phase 1 / 2a trial of anti - TNFR2 antibody BI - 1808 . Financial information FIRST QUARTER 2021 • Net sales SEK 6.2 ( 16.7 ) million . • Loss after tax SEK -79.8 ( -32.6 ) million . • Loss after tax per share before and after dilution SEK -1.94 ( -1.63 ) . • Cash flow from operating activities and investment activities SEK -51.5 ( -35.4 ) million . Liquid funds as of March 31 , 2021 : SEK 1,577.1 ( 117.1 ) million . ( R ) Regulatory event The information was submitted for publication at 8:00 a.m. CEST on April 28 , 2021 . O